Effectiveness of Pharmaceutical Care in Reducing the Incidence of Immune Checkpoint Inhibitor-related Pneumonitis in Patients with NSCLC: A Randomized Controlled Trial.
文献摘要
Background Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of non-small cell lung cancer (NSCLC), yet immune checkpoint inhibitor-related pneumonitis (CIP) remains a potentially life-threatening adverse event that may be mitigated through structured pharmaceutical care interventions. Objective To assess the effectiveness of pharmacy services in reducing the occurrence of CIP among patients with NSCLC receiving ICIs. Methods Patients who underwent immunotherapy at our hospital between November, 2023 to September, 2024 were selected and randomized into the control and intervention groups (105 patients each). Intervention group received 6 months of pharmacy services, and CIP occurrence, clinical efficacy, medication adherence, and quality of life at 3, 6, and 9 months were compared between the two groups. Results Compared with the control group, the intervention group had a significantly lower CIP incidence and immunotherapy suspension rate due to CIP (2.9% vs. 9.5%, P = 0.043), as well as significantly improved medication adherence at all time points (P Conclusions Pharmacy care can reduce the incidence and severity, and increase the onset time of CIP, thus enhancing drug safety.